EP0548238A1 - Suspensions orales liquides non aqueuses - Google Patents

Suspensions orales liquides non aqueuses

Info

Publication number
EP0548238A1
EP0548238A1 EP91917176A EP91917176A EP0548238A1 EP 0548238 A1 EP0548238 A1 EP 0548238A1 EP 91917176 A EP91917176 A EP 91917176A EP 91917176 A EP91917176 A EP 91917176A EP 0548238 A1 EP0548238 A1 EP 0548238A1
Authority
EP
European Patent Office
Prior art keywords
composition
cimetidine
oil
antagonist
oily vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91917176A
Other languages
German (de)
English (en)
Inventor
Malcolm 8 Morris Way Foreman
Harvey Lee Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0548238A1 publication Critical patent/EP0548238A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the triglycerides of the C 8 -C 10 fatty acids of fractionated coconut oil which are available under the trade name of "Miglyol".
  • Miglyol is a triglyceride of capric and caprylic acids with glycerol.
  • the oils may also include sugar fatty acids known as "Olestras”.
  • the partially hydrogenated soybean oils are particularly preferred.
  • a species of this group of edible vegetable oils is commercially available under the trade name of "Durkex”. Most preferably, Durkex 25 is employed in the compositions of this invention.
  • Sugars such as, for example, mannitol, sorbitol,
  • compositions of this invention is within the skill of the pharmaceutical art except as specifically set forth herein.
  • the compositions are prepared following the conventional techniques well known to those skilled in the art involving variously mixing, suspending and dispersing the ingredients as appropriate to give the desired composition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions liquides pharmaceutiquement élégantes et administrées par voie orale comprenant un antagoniste d'histamine H2 tel que la cimétidine dans un véhicule huileux comestible. Les compositions ont un goût très agréable et elles réduisent au minimum le goût amer associé à ces composés. On peut facultativement ajouter d'autres additifs pharmaceutiques bien connus en la matière.
EP91917176A 1990-09-13 1991-09-10 Suspensions orales liquides non aqueuses Withdrawn EP0548238A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58186690A 1990-09-13 1990-09-13
US581866 1990-09-13

Publications (1)

Publication Number Publication Date
EP0548238A1 true EP0548238A1 (fr) 1993-06-30

Family

ID=24326890

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91917176A Withdrawn EP0548238A1 (fr) 1990-09-13 1991-09-10 Suspensions orales liquides non aqueuses

Country Status (7)

Country Link
EP (1) EP0548238A1 (fr)
JP (1) JPH06501003A (fr)
AU (1) AU8546591A (fr)
NZ (1) NZ239784A (fr)
PT (1) PT98975A (fr)
WO (1) WO1992004893A1 (fr)
ZA (1) ZA917310B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3476447A (en) * 1968-03-28 1969-11-04 Westinghouse Electric Corp Self-aligning hydrostatic bearing
MX9306393A (es) * 1992-10-16 1994-04-29 Glaxo Group Ltd Composiciones de ranitidina substancialmente libres de sabor amargo, proceso para su preparacion y composiciones farmaceuticas que las contienen.
GB9224855D0 (en) * 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
US5484800A (en) * 1994-08-30 1996-01-16 American Home Products Corporation Lipid-based liquid medicinal composition
GB9418530D0 (en) * 1994-09-14 1994-11-02 Glaxo Group Ltd Medicaments
AU7468096A (en) * 1995-10-30 1997-05-22 Warner-Lambert Company Enhanced anti-inflammatory oral composition containing h2 receptor antagonist and antimicrobial oils
ES2153786B1 (es) * 1999-06-10 2001-10-16 S A L V A T Lab Sa Composicion farmaceutica liquida para la administracion oral de principios activos amargos y susceptibles de hidrolisis.
WO2003047336A2 (fr) 2001-11-30 2003-06-12 Abgenix, Inc. Animaux transgeniques porteurs de genes a chaine legere $g(l) d'immunoglobuline humaine
WO2004004682A2 (fr) * 2002-07-02 2004-01-15 Laboratorios S.A.L.V.A.T., S.A. Formulation pharmaceutique orale de microgranules en suspension, stable a long terme
US20040202696A1 (en) * 2003-04-14 2004-10-14 Cts Chemical Industries Ltd. Administration form for veterinary use
WO2006008640A1 (fr) * 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Suspension non aqueuse contenant un medicament a gout desagreable
CN101610754A (zh) * 2007-02-16 2009-12-23 Aska制药株式会社 含有微粒油性混悬液的药物组合物
EP2910571B1 (fr) 2008-03-18 2016-10-05 Novo Nordisk A/S Analogues de l'insuline acylés, stabilisés à la protéase
CN102481343A (zh) * 2009-09-16 2012-05-30 诺沃—诺迪斯克有限公司 稳定的含胰岛素的非水液体药物组合物
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
GB2529605B (en) * 2014-06-03 2018-03-21 Essential Pharmaceuticals Ltd Pharmaceutical composition
BR102015024165A2 (pt) * 2015-09-18 2017-03-28 Prati Donaduzzi & Cia Ltda composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
MA49116A (fr) 2016-12-16 2020-03-25 Novo Nordisk As Compositions pharmaceutiques contenant de l'insuline
CN112020350A (zh) 2018-04-27 2020-12-01 强生消费者公司 液体口服药物剂型

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0684420B2 (ja) * 1986-12-26 1994-10-26 三菱レイヨン株式会社 活性エネルギ−線硬化性樹脂組成物
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9204893A1 *

Also Published As

Publication number Publication date
PT98975A (pt) 1992-07-31
AU8546591A (en) 1992-04-15
NZ239784A (en) 1994-05-26
JPH06501003A (ja) 1994-01-27
WO1992004893A1 (fr) 1992-04-02
ZA917310B (en) 1992-10-28

Similar Documents

Publication Publication Date Title
EP0548238A1 (fr) Suspensions orales liquides non aqueuses
US5059626A (en) Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
US4918103A (en) Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
US6806256B2 (en) Taste masked liquid pharmaceutical compositions
FR2727016A1 (fr) Compositions pharmaceutiques a base d'ondansetron
FR2727015A1 (fr) Compositions pharmaceutiques liquides a base d'ondansetron
EP0043616A2 (fr) Compositions comestibles et pharmaceutiques et leurs procédés de préparation
US4259323A (en) Potassium chloride emulsion
US5011852A (en) Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
CA1333773C (fr) Compositions antitussives liquides contenant du phenol
WO2000066170A1 (fr) Solution orale de prucalopride
US5534552A (en) Clear non-alcoholic sinus and allergy medication
IE913216A1 (en) Non-aqueous liquid oral suspensions
US6235733B1 (en) Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors
US6265449B1 (en) Aqueous compositions comprising ranitidine and LCMT sucrose
US20050136116A1 (en) Stabilized prednisolone sodium phosphate solutions
US20020061884A1 (en) Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors
US20060127472A1 (en) Taste-masked prednisolone oral formulations
JPH0672897A (ja) 月経前の及び月経の不快な諸症状を軽減するための組成物
MXPA00007579A (en) Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930326

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI NL

17Q First examination report despatched

Effective date: 19950427

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950907